IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints

Immunovant slips 2.4% after batoclimab misses key phase III endpoints in thyroid eye disease trials, despite stable safety and signs of biological activity.

Zacks Investment Research • Apr 6, 2026

Immunovant's treatment for eye disease fails late-stage trial

Immunovant ​said on ‌Thursday ​that ​its therapy ⁠to ​treat a ​type of ​eye ​disease failed to ‌meet ⁠the main ​goals ​in ⁠a ​late-stage ​study.

Reuters • Apr 2, 2026

Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript

Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript

Seeking Alpha • Apr 2, 2026

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?

Logos added 1.1 million shares of Immunovant last quarter, a purchase estimated at about $24.5 million based on quarterly average pricing. By quarter's end, the position had grown to roughly $35 million, reflecting both the new shares and price gains during the period.

The Motley Fool • Mar 15, 2026

Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish

Alpine Global Management sold 128,039 shares of Immunovant in the fourth quarter; the estimated transaction value was $2.8 million based on quarterly average prices. Meanwhile, the quarter-end position value decreased by $22 million, reflecting both trading and stock price changes.

The Motley Fool • Mar 11, 2026

Immunovant Stock Surges 17% in 3 Months: What's Driving It?

IMVT gains 17% in three months as IMVT-1402 advances across autoimmune trials, with multiple data readouts due in 2026-2027, and $994.5M cash backing development.

Zacks Investment Research • Mar 5, 2026

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ:IMVT) on behalf of the company's shareholders.  The investigation seeks to determine whether Immunovant, Inc.'s directors breached their fiduciary duties in connection with recent corporate actions.

PRNewsWire • Feb 17, 2026

IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus

Immunovant beats third-quarter estimates, raises $550M to fund IMVT-1402 through launch and advances multiple studies with key data ahead.

Zacks Investment Research • Feb 9, 2026

Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript

Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript

Seeking Alpha • Feb 6, 2026

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

DURHAM, N.C., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported its financial results for the third quarter ended December 31, 2025.

GlobeNewsWire • Feb 6, 2026